Abbott Settles TriCor Patent Spat With Teva
In a filing Monday with the U.S. Securities and Exchange Commission, Abbott said it had granted Teva the rights to the 145-milligram dose of TriCor no sooner than March 28, 2011. Under certain unspecified circumstances, Teva may not get rights to the patents until July 1, 2012, the filing says.
The filing does not specify in which...
To view the full article, register now.